An exploratory study of the fusion co-mutated immune microenvironment in Non-small cell lung cancer

Lead Investigator: Qingyun Li, Genecast Biotechnology Co., Ltd
Title of Proposal Research:  An exploratory study of the fusion co-mutated immune microenvironment in Non-small cell lung cancer
Vivli Data Request: 7804
Funding Source: None
Potential Conflicts of Interest: None


Summary of the Proposed Research:

The incidence of non-small cell lung cancer (NSCLC) in China in men is about 50 cases per 100,000 people, and in women it is closer to 30 per 100,000.

A fusion gene is when two genes are joined at the beginning and end to form a new gene. As technology has developed, fusion genes have been identified more frequently in lung cancer, with the ALK receptor tyrosine kinase (ALK) / ret proto-oncogene (RET) / ROS proto-oncogene 1 receptor tyrosine kinase (ROS1) rearrangements are the most common genes. A patient who has a fusion with another type of variations is known as a co-mutant. Patients with ALK fusions are usually treated with ALK-specific tyrosine kinase inhibitors (TKIs), but patients with co-mutant are less effective with ALK-TKIs. The aim of this article is to explore the reasons for the differences in efficacy in patients with and without co-mutations and to provide an immune microenvironmental perspective. In the long term, the prognosis of patients and the efficacy of treatment can be predicted by whether they have a co-mutation or not, and provide more precise treatment options for these co-mutant patients.

The present study is a retrospective analysis of the differences between the two groups of cases with and without the co-mutation to provide an insight into the prognosis of the patients. And it will study the differences in their immune microenvironment to find out if there are statistically significant differences.


Requested Studies:

A Phase III, Open-Label, Randomized Study of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Carboplatin+Paclitaxel With or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer
Data Contributor: Roche
Study ID: NCT02366143
Sponsor ID: GO29436

Update: This data request was withdrawn on 6-Jul-2023 by the researcher.